Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 8/20 | 0.57 |
| ▸ | CTSS | P25774 | 7/20 | 0.57 |
| ▸ | CTSL | P07711 | 6/20 | 0.57 |
| ▸ | CTSB | P07858 | 3/20 | 0.57 |
| ▸ | CTSV | O60911 | 2/20 | 0.51 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.50 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.48 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.48 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.48 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.48 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.44 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.44 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6485879 | 1.00 | CTSK (0.57) | CTSKCTSSCTSLCTSBCTSV | |
| SCHEMBL6488824 | 0.99 | CTSK (0.55) | CTSKCTSSCTSLCTSBCTSV | |
| SCHEMBL6488830 | 0.99 | CTSK (0.55) | CTSKCTSSCTSLCTSBCTSV | |
| SCHEMBL6483630 | 0.89 | CTSS (0.55) | CTSKCTSSCTSLCTSBCTSV | |
| SCHEMBL6483624 | 0.89 | CTSS (0.55) | CTSKCTSSCTSLCTSBCTSV | |
| SCHEMBL6487184 | 0.88 | CTSK (0.49) | CTSKCTSSCTSLCTSBCTSV | |
| SCHEMBL6484631 | 0.88 | CTSK (0.53) | CTSKCTSSCTSLCTSBCTSV | |
| SCHEMBL6484623 | 0.88 | CTSK (0.53) | CTSKCTSSCTSLCTSBCTSV | |
| SCHEMBL6485762 | 0.87 | CTSK (0.53) | CTSKCTSSCTSLCTSBCTSV | |
| SCHEMBL6485772 | 0.87 | CTSK (0.53) | CTSKCTSSCTSLCTSBCTSV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050020588-A1 | Cysteine protease inhibitors | PEPTIMMUNE, INC. | 2005-01-27 | — | — | US | claimed |
| US-20030203900-A1 | Cysteine protease inhibitors | MEDIVIR UK LTD (GB) | 2003-10-30 | — | — | US | claimed |
| EP-1345931-A2 | CYSTEINE PROTEASE INHIBITORS | Medivir UK Ltd (GB) | 2003-09-24 | — | — | EP | claimed |
| WO-2002040462-A2 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR UK LIMITED (GB) | 2002-05-23 | — | — | WO | claimed |
| US-20050020588-A1 | Cysteine protease inhibitors | PEPTIMMUNE, INC. | 2005-01-27 | — | — | US | disclosed |
| US-20030203900-A1 | Cysteine protease inhibitors | MEDIVIR UK LTD (GB) | 2003-10-30 | — | — | US | disclosed |
| EP-1345931-A2 | CYSTEINE PROTEASE INHIBITORS | Medivir UK Ltd (GB) | 2003-09-24 | — | — | EP | disclosed |
| WO-2002040462-A2 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR UK LIMITED (GB) | 2002-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020588-A1 | Cysteine protease inhibitors | CTSS, CTSE, CTSV | CTSK 4/4885CTSS 1/4885CTSL 11/4885 |
| US-20030203900-A1 | Cysteine protease inhibitors | CTSS, CTSE, CTSV | CTSK 4/4885CTSS 1/4885CTSL 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.